ArticleCancer biomarkers : section A of Disease markers2020
Deep learning-based model for predicting progression in patients with head and neck squamous cell carcinoma.
Article in Cancer biomarkers : section A of Disease markers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- A deep learning fusion network trained with medical records and laryngoscopic images in the early diagnosis of glottic carcinoma.iScience · 2025Article
- Combined prognostic value of preoperative serum thyrotrophin and thyroid hormone concentration in papillary thyroid cancer.Journal of clinical laboratory analysis · 2022Article
- Multimodal deep learning for biomedical data fusion: a review.Briefings in bioinformatics · 2022Review
- Deep Learning-Based Multi-Omics Integration Robustly Predicts Relapse in Prostate Cancer.Frontiers in oncology · 2022Article
- An Unsupervised Deep Learning-Based Model Using Multiomics Data to Predict Prognosis of Patients with Stomach Adenocarcinoma.Computational and mathematical methods in medicine · 2022Article
- The landscape of tumors-infiltrate immune cells in papillary thyroid carcinoma and its prognostic value.PeerJ · 2021Article
- Molecular Subtypes of Oral Squamous Cell Carcinoma Based on Immunosuppression Genes Using a Deep Learning Approach.Frontiers in cell and developmental biology · 2021Article
- Deep Learning in Head and Neck Tumor Multiomics Diagnosis and Analysis: Review of the Literature.Frontiers in genetics · 2021Review
- Deep Learning Reveals Key Immunosuppression Genes and Distinct Immunotypes in Periodontitis.Frontiers in genetics · 2021Article
- Recent Advances in the Application of Artificial Intelligence in Otorhinolaryngology-Head and Neck Surgery.Clinical and experimental otorhinolaryngology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study endeavors to build a deep learning (DL)-based model for predicting disease progression in head and neck squamous cell carcinoma (HNSCC) patients by integrating multi-omics data.
methodsRNA sequencing, miRNA sequencing, and methylation data from The Cancer Genome Atlas (TCGA) were used as input for autoencoder, a DL approach. An autoencoder-based prognosis model for PFS was built by SVM algorithm and tested in three confirmation sets. Predictive performance of the model was compared to two alternative approaches. Differential expression analysis for mRNAs, microRNAs (miRNA) and methylation was conducted. Moreover, functional annotation of differentially expressed genes (DEGs) was achieved through function enrichment analysis.
resultThe DL-based prognosis model identified two subgroups of patients with significantly different PFS, and showcased a good model fitness (C-index = 0.73). The two identified PFS subtypes were successfully validated in three confirmation sets. The DL-based model was more accurate and efficient than principal component analysis (PCA) or individual Cox-PH-based models. There were 348 DEGs, 23 differentially expressed miRNAs and 55 differentially methylated genes between the two PFS subtypes. These genes were significantly involved in several immune-related biological processes and primary immunodeficiency, cell adhesion molecules (CAMs), B cell receptor signaling and leukocyte transendothelial migration pathways.
conclusionThe DL-based model introduced in this study is reliable and robust in predicting disease progression in HNSCC patients. A number of pathways and genes targets are unraveled to be implicated in cancer progression. Utility of this model would facilitate development of more individualized therapy for HNSCC patients and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.